Peptides for Spinal Muscular Atrophy: Enhancing Therapeutic Deliver...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides are crucial in Spinal Muscular Atrophy (SMA) therapy, primarily by improving the delivery of antisense oligonucleotides to enhance SMN protein production. Novel peptides like r6 and RXR, and therapeutic agents like Apitegromab, are showing promise in restoring motor function and increasing SMN levels.

Spinal Muscular Atrophy: A Genetic Challenge to Motor Function

Spinal Muscular Atrophy (SMA) is a devastating genetic neuromuscular disorder characterized by the progressive loss of motor neurons, leading to muscle weakness, atrophy, and in severe cases, paralysis and respiratory failure. The primary cause of SMA is a deficiency in the Survival Motor Neuron (SMN) protein, due to mutations in the SMN1 gene. While significant advancements have been made with gene therapies and SMN-enhancing drugs, a key challenge remains in effectively delivering these treatments to the target cells. Peptides are emerging as vital tools in overcoming these delivery hurdles and directly influencing muscle health in SMA.

Peptide-Conjugated Morpholino Oligomers (PPMOs): A Delivery Revolution

One of the most impactful applications of peptides in SMA therapy is their role in enhancing the delivery of antisense oligonucleotides (ASOs). ASOs work by modifying the splicing of the SMN2 gene, a "backup" gene that can produce some functional SMN protein. However, ASOs often struggle to cross biological barriers and reach target cells efficiently. This is where Cell-penetrating peptide-conjugated Morpholino Oligomers (PPMOs) come into play. PPMOs combine the therapeutic power of morpholino ASOs with the enhanced cellular uptake capabilities of specific peptides. Studies have shown that peptides like r6 and RXR, when conjugated to morpholinos, are highly effective in rescuing SMN protein levels compared to unconjugated morpholinos (Bersani et al., 2021). This systemic peptide-mediated oligonucleotide therapy significantly improves the long-term survival and motor function in SMA animal models (Hammond et al., 2016).

Targeting Both CNS and Peripheral Muscles

The beauty of advanced peptide-oligonucleotide conjugates, such as Pip6a-morpholino phosphorodiamidate oligomer (PMO), is their demonstrated efficacy in both the central nervous system (CNS) and peripheral muscles. This broad distribution is critical for SMA, as both motor neurons in the spinal cord and the skeletal muscles themselves are affected. By ensuring that the therapeutic agent reaches these diverse tissues, peptides help maximize the production of functional SMN protein where it's needed most, leading to more comprehensive improvements in motor function.

Apitegromab: A Myostatin Inhibitor for Muscle Improvement

Beyond delivery, peptides and peptide-like molecules are also being explored for their direct effects on muscle health in SMA. Apitegromab, for instance, is a therapeutic agent that targets myostatin, a protein that inhibits muscle growth. By inhibiting myostatin, Apitegromab aims to promote muscle growth and improve motor function in SMA patients. Clinical and preclinical evidence suggests that Apitegromab has the potential to enhance muscle mass and strength, thereby complementing SMN-restoring therapies by directly addressing the muscle weakness and atrophy that are hallmarks of SMA (Scholar Rock, n.d.). This represents a different, yet complementary, strategy to improve the quality of life for individuals with SMA.

Practical Takeaway for Patients

For individuals and families navigating Spinal Muscular Atrophy, the advancements in peptide-based therapies offer significant hope. These innovative approaches are not only making existing treatments more effective by improving drug delivery but are also introducing new ways to directly enhance muscle function. It's vital to maintain close communication with your medical team to stay informed about the latest research, clinical trials, and available therapeutic options. Discussing the potential benefits of peptide-enhanced therapies, alongside established treatments like Spinraza, Risdiplam, and Zolgensma, can help tailor a comprehensive treatment plan aimed at maximizing motor function and improving overall quality of life.